Welcome to our dedicated page for Mesa Laboratories SEC filings (Ticker: MLAB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Mesa Laboratories SEC filings document the company's life sciences tools and critical quality control business, its Nasdaq-listed common stock and formal disclosures around operating results, governance and capital structure. Form 8-K reports furnish quarterly financial releases, record annual meeting voting outcomes and report executive succession, director changes and related compensation arrangements.
Other filings and exhibits describe the company's credit facility borrowings, convertible note settlement funding, independent auditor ratification, board committee structure and proxy compensation disclosures. These records frame Mesa's disclosure obligations across its four operating divisions and its financing, shareholder-vote and leadership-transition matters.
Mesa Laboratories Inc. (MLAB) – Form 4 insider transaction dated 06/18/2025
Senior Vice-President of Operations Brian D. Archbold reported the automatic conversion of 2,556 restricted stock units (RSUs) into common shares (Transaction Code M) at a reference price of $92.99 per share. To cover tax obligations, he simultaneously disposed of 1,166 shares via a tax-withholding transaction (Code F) at the same price.
Post-transaction direct holdings changed as follows:
- Common stock: 1,948 shares now held directly (down from 3,114 immediately after the RSU conversion).
- Unvested/remaining RSUs: 4,960 units retained, scheduled to vest one-third on 18 June 2025 and on each of the next two anniversaries.
The activity reflects routine equity compensation vesting rather than an open-market purchase or sale; no cash was exchanged for the share acquisition portion.
Mesa Laboratories, Inc. (MLAB) – Form 4 insider transaction filed 06/20/2025
CFO John Sakys reported activity dated 06/18/2025 involving the exercise and settlement of restricted stock units (RSUs) and related tax withholding.
- RSU exercise (Code M): 2,840 common shares were issued upon vesting of previously granted RSUs. Each RSU converts 1-for-1 into common stock.
- Tax withholding (Code F): 1,243 of the newly issued shares were automatically withheld at a reference price of $92.99 to satisfy tax obligations.
After the transactions, Sakys’ direct beneficial ownership changed from 12,865 shares to 14,462 shares, a net increase of 1,597 shares (≈12.4%).
The RSU award vests in three equal annual installments beginning 06/18/2025, providing future potential share deliveries on the next two anniversary dates.
No derivative positions remain other than 5,511 unvested RSUs outstanding.
Because the share acquisition arose from planned equity compensation rather than open-market buying, the filing signals routine ownership growth rather than an active market purchase, though the net increase modestly aligns the CFO’s incentives with shareholders.